Mastodon

Bacteriophagum proteus (Solution) Instructions for Use

Marketing Authorization Holder

Microgen NPO, JSC (Russia)

ATC Code

V03A (Other therapeutic agents)

Dosage Form

Bottle OTC Icon Bacteriophagum proteus Solution for oral, topical and external use: bottle 20 ml 4 or 10 pcs. or 100 ml 1 pc.

Dosage Form, Packaging, and Composition

Solution for oral, topical and external use in the form of a clear liquid of yellow color of varying intensity, a greenish tint is possible.

1 ml
Sterile purified filtrate of phagolysates of bacteria Proteus vulgaris, Proteus mirabilis (with activity according to Appelman – not less than 10-5) 100%

Excipients : preservative – 8-hydroxyquinoline sulfate / 8-hydroxyquinoline sulfate monohydrate in terms of 8-hydroxyquinoline sulfate – 0.0001 g/ml (calculated content).

20 ml – bottles (4) – cardboard packs.
20 ml – bottles (10) – cardboard packs.
100 ml – bottles (1) – cardboard packs.

Clinical-Pharmacological Group

Immunobiological drug – bacteriophage

Pharmacotherapeutic Group

Other therapeutic products

Pharmacological Action

It has the ability to specifically lyse Proteus bacteria.

Indications

Treatment and prevention of purulent-inflammatory and enteral diseases caused by bacteria P. vulgaris, P. mirabilis as part of complex therapy: diseases of the ear, throat, nose, respiratory tract and lungs (inflammation of the sinuses, middle ear, tonsillitis, pharyngitis, laryngitis, tracheitis, bronchitis, pneumonia, pleurisy); surgical infections (wound suppuration, burns, abscess, phlegmon, boils, carbuncles, hidradenitis, felons, paraproctitis, mastitis, bursitis, osteomyelitis); urogenital infections (urethritis, cystitis, pyelonephritis, colpitis, endometritis, salpingo-oophoritis); enteral infections (gastroenterocolitis, cholecystitis), intestinal dysbiosis; generalized septic diseases; purulent-inflammatory diseases of newborns (including omphalitis, pyoderma, conjunctivitis, gastroenterocolitis, sepsis); other diseases caused by Proteus bacteria.

For prophylactic purposes, it is used for the treatment of postoperative and freshly infected wounds, as well as for the prevention of nosocomial infections for epidemic indications.

ICD codes

ICD-10 code Indication
A09 Other and unspecified gastroenteritis and colitis of infectious origin
A41 Other sepsis
B96.4 Proteus (mirabilis) (morganii) as the cause of diseases classified in other chapters
H66 Suppurative and unspecified otitis media
J00 Acute nasopharyngitis (common cold)
J01 Acute sinusitis
J02 Acute pharyngitis
J03 Acute tonsillitis
J04 Acute laryngitis and tracheitis
J15 Bacterial pneumonia, not elsewhere classified
J20 Acute bronchitis
J31.1 Chronic nasopharyngitis
J31.2 Chronic pharyngitis
J32 Chronic sinusitis
J35.0 Chronic tonsillitis
J37 Chronic laryngitis and laryngotracheitis
J42 Unspecified chronic bronchitis
J86 Pyothorax (pleural empyema)
K61 Abscess of anal and rectal regions
K63.8 Other specified diseases of intestine
K81.0 Acute cholecystitis
K81.1 Chronic cholecystitis
L02 Cutaneous abscess, furuncle and carbuncle
L03 Cellulitis
L08.0 Pyoderma
L73.2 Hidradenitis suppurativa
M70 Soft tissue disorders related to use, overuse, and pressure
M71 Other bursopathies
M86 Osteomyelitis
N10 Acute tubulointerstitial nephritis (acute pyelonephritis)
N11 Chronic tubulointerstitial nephritis (chronic pyelonephritis)
N30 Cystitis
N34 Urethritis and urethral syndrome
N61 Inflammatory diseases of the breast
N70 Salpingitis and oophoritis
N71 Inflammatory disease of uterus, excluding cervix (including endometritis, myometritis, metritis, pyometra, uterine abscess)
N72 Inflammatory disease of cervix uteri (including cervicitis, endocervicitis, exocervicitis)
N76 Other inflammatory diseases of vagina and vulva
O91 Infections of the breast associated with childbirth
P36 Bacterial sepsis of newborn
P38 Omphalitis of newborn with or without mild hemorrhage
P39.1 Neonatal conjunctivitis and dacryocystitis
P39.4 Neonatal skin infection
P78.8 Other specified disorders of the digestive system in the perinatal period
R09.1 Pleurisy
T79.3 Posttraumatic wound infection, not elsewhere classified
Z29.8 Other specified prophylactic measures
ICD-11 code Indication
1A40.Z Infectious gastroenteritis or colitis, unspecified
1B70.1 Streptococcal cellulitis of the skin
1B70.2 Staphylococcal cellulitis of the skin
1B70.Z Bacterial cellulitis or lymphangitis caused by unspecified bacterium
1B75.0 Furuncle
1B75.1 Carbuncle
1B75.2 Furunculosis
1B75.3 Pyogenic skin abscess
1G40 Sepsis without septic shock
AA9Z Unspecified suppurative otitis media
CA00 Acute nasopharyngitis
CA01 Acute rhinosinusitis
CA02.Z Acute pharyngitis, unspecified
CA03.Z Acute tonsillitis, unspecified
CA05 Acute laryngitis or tracheitis
CA09.1 Chronic nasopharyngitis
CA09.2 Chronic pharyngitis
CA0A.Z Chronic rhinosinusitis, unspecified
CA0F.Y Other specified chronic diseases of the palatine tonsils and adenoids
CA0G Chronic laryngitis or laryngotracheitis
CA20.1Z Chronic bronchitis, unspecified
CA40.0Z Bacterial pneumonia, unspecified
CA42.Z Acute bronchitis, unspecified
CA44 Pyothorax
DA92.1 Pneumatosis intestinalis of the small intestine
DA98.Z Polyps of small intestine, unspecified
DB31.1 Pneumatosis of the colon
DB36.Z Certain infections of the colon, unspecified
DB70.0Z Abscess of anal and rectal region, unspecified
DC12.0Z Acute cholecystitis, unspecified
DC12.1 Chronic cholecystitis
DE2Z Diseases of the digestive system, unspecified
EB21 Pyoderma gangrenosum
ED92.0 Hidradenitis suppurativa
EH1Z Neonatal infection of the skin, unspecified
FB50.1 Bursitis associated with use, overuse or pressure
FB50.Z Bursitis, unspecified
FB84.Z Osteomyelitis or osteitis, unspecified
GA00 Vulvitis
GA01.Z Inflammatory diseases of uterus, except cervix, unspecified
GA02.Z Unspecified vaginitis
GA07.Z Salpingitis and oophoritis, unspecified
GA0Z Inflammatory diseases of female genital tract, unspecified
GB21.Z Inflammatory diseases of the breast, unspecified
GB50 Acute tubulo-interstitial nephritis
GB51 Acute pyelonephritis
GB55.Z Chronic tubulo-interstitial nephritis, unspecified
GB5Z Renal tubulo-interstitial diseases, unspecified
GC00.Z Cystitis, unspecified
GC02.Z Urethritis and urethral syndrome, unspecified
JB45.Z Infections of the breast associated with childbirth, unspecified
KA60 Fetal or neonatal sepsis
KA65.0 Conjunctivitis or dacryocystitis of newborn
KA65.1 Omphalitis of newborn
KB80 Gastro-esophageal reflux disease in newborns
KB81.0 Eosinophilic esophagitis in newborns
KB8Z Digestive system disorders of fetus or newborn, unspecified
MD31 Pleurisy
NF0A.3 Posttraumatic wound infection, not elsewhere classified
QC05.Z Prophylactic measures, unspecified
XN3BS Proteus
GA0Z Inflammatory diseases of female genital tract, unspecified
XA5WW1 Cervix uteri

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Determine the dosage regimen individually based on the patient’s age and the specific clinical indication.

Administer the solution orally on an empty stomach, 1 hour before a meal.

For rectal administration, use the drug in the form of enemas after bowel evacuation.

Apply topically for irrigation, lotions, and tamponage of affected areas and wound cavities.

Introduce into body cavities such as the pleural, articular, and other drained spaces.

Use for instillation into the nose, sinuses, vagina, and uterus.

For oral administration in adults and children over 8 years old, use a single dose of 20-30 ml.

For children aged 3 to 8 years, administer 15-20 ml per dose.

For children from 1 to 3 years old, use 10-15 ml per dose.

For infants 6 to 12 months old, administer 10 ml per dose.

For infants under 6 months old, use 5 ml per dose.

Administer the drug orally twice daily for the treatment of enteral infections and intestinal dysbiosis.

For other indications, administer orally three times daily.

For high rectal administration in adults and children over 8 years old, use a single dose of 40-60 ml.

For children aged 3 to 8 years, administer 30-40 ml per rectal dose.

For children from 1 to 3 years old, use 20-30 ml per rectal dose.

For infants 6 to 12 months old, administer 10-20 ml per rectal dose.

For infants under 6 months old, use 10 ml per rectal dose.

Administer rectally once daily. The standard treatment course is 7 to 10 days based on clinical response.

For purulent-inflammatory diseases with localized lesions, apply the solution topically in addition to oral or rectal administration.

Irrigate, rinse, or apply moistened gauze pads to affected areas 2-3 times daily.

Introduce into drained cavities 10 to 200 ml once daily.

For purulent otitis, instill 2-5 drops into the ear or insert turundas soaked in the solution 1-3 times daily.

For tonsillitis, pharyngitis, or laryngitis, gargle with 10-20 ml of solution 2-3 times daily.

For conjunctivitis, instill 4-5 drops into each eye 2-3 times daily.

For styes, apply a moistened gauze pad to the affected eyelid 2-3 times daily.

For sinusitis or rhinitis, instill 5-10 drops into each nasal passage 2-3 times daily.

For cystitis, pyelonephritis, and urethritis, administer the solution into the bladder or renal pelvis via cystostomy or ureteral catheter, 20-50 ml once daily.

For colpitis and endometritis, administer 5-10 ml intravaginally once daily or use for irrigation with 10-20 ml.

For intestinal dysbiosis, administer orally or rectally for 7 to 10 days.

For prophylactic purposes in treated surgical wounds, apply the solution once daily throughout the risk period.

Adverse Reactions

Not established.

Contraindications

Hypersensitivity to the components of the bacteriophage.

Use in Pregnancy and Lactation

The use of the bacteriophage during pregnancy and breastfeeding is possible in the presence of infections caused by phage-sensitive strains of bacteria (as recommended by a doctor).

Pediatric Use

The drug is approved for use in children and adolescents under 18 years of age.

Special Precautions

An important condition for effective phage therapy is the preliminary determination of the phage sensitivity of the pathogen.

Drug Interactions

The use of the bacteriophage does not exclude the use of other antibacterial drugs.

Storage Conditions

Store at 2°C (36°F) to 8°C (46°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS